ArticleFrontiers in medicine2026
A real-world comparison of transcatheter edge-to-edge repair versus surgical mitral valve intervention in patients with mitral regurgitation: a TriNetX study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Clinical outcomes of tricuspid transcatheter edge-to-edge repair in patients with tricuspid regurgitation.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to compare the clinical outcomes of transcatheter edge-to-edge repair (TEER) and surgical repair in patients with non-rheumatic mitral regurgitation (MR) using real-world data. Methods: We conducted a retrospective cohort study using TriNetX to identify adults with mitral regurgitation who underwent surgical repair or TEER (2013-2025). Propensity score matching (PSM) balanced demographics, comorbidities, and medications. The primary outcome was all-cause mortality; the secondary outcomes included cardiovascular events. Results: After exclusions, 35,753 patients with mitral regurgitation were identified, including 2,165 TEER and 33,588 surgical cases; 2,029 matched pairs were analyzed. At 1 year, surgery showed lower mortality (hazard ratio [HR]: 0.78; 95% confidence interval [CI]: 0.64-0.96), primarily between 2 months and 1 year. Surgery was associated with higher rates of early dyspnea, atrial fibrillation, and heart failure, though heart failure could be reversed later. No significant differences were found in major adverse cardiovascular events (MACEs), stroke, acute myocardial infarction (AMI), cardiac arrest, or emergency department (ED) visits. A subgroup analysis of patients with mitral valve prolapse showed consistent results, with atrial fibrillation and heart failure occurring more frequently after surgery. Conclusion: In this large cohort, surgery and TEER produced different outcomes. Early mortality was similar, but surgery improved survival after 2 months. TEER had fewer early dyspnea, atrial fibrillation, and heart failure events. No differences were observed in MACE, stroke, AMI, or ED visits, supporting individualized MR treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.